A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC

Background/Aims: Lenvatinib was recently approved as a first-line oral multikinase inhibitor for unresectable hepatocellular carcinoma (HCC). In this study, we aimed to compare the efficacy and safety of lenvatinib and sorafenib for the treatment of unresectable HCC in patients with prior failure of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Med
Main Authors: Lee, Jaejun, Sung, Pil Soo, Yang, Hyun, Lee, Soon Kyu, Nam, Hee Chul, Yoo, Sun Hong, Lee, Hae Lim, Kim, Hee Yeon, Lee, Sung Won, Kwon, Jung Hyun, Jang, Jeong Won, Kim, Chang Wook, Nam, Soon Woo, Bae, Si Hyun, Choi, Jong Young, Yoon, Seung Kew
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7767204/
https://ncbi.nlm.nih.gov/pubmed/33371271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9124121
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados